The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval

Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval

September 27, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Friday, Sept. 23, will be another day marked in history for those treating autoimmune diseases. The FDA has approved adalimumab-atto, also known as Amjevita, which is a biosimilar to adalimumab (Humira).1 Adalimumab-atto has received approval only for the following indications of the innovator product:

You Might Also Like
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
Also By This Author
  • Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
  • In adult patients with:
    —Moderate to severe active rheumatoid arthritis
    —Active psoriatic arthritis;
    —Active ankylosing spondylitis;
    —Moderate to severe active Crohn’s disease;
    —Moderate to severe active ulcerative colitis; and
    —Moderate to severe plaque psoriasis; as well as
  • In patients ages 4 years and older with:
    —moderate to severe active polyarticular juvenile idiopathic arthritis.

The approval of adalimumab-atto was based on a review of evidence, including structural and functional characterization, animal studies, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrated its biosimilarity to the reference product, adalimumab. Adalimumab-atto has not been approved for all indications of the reference product, and interchangeability has not yet been determined. All dosing, administration, warnings and precautions, contraindications and boxed warnings of adalimumab-atto (Amjevita) match those of adalimumab (Humira).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although the treatment is FDA approved, the availability of adalimumab-atto will be delayed due to a required 180-day notice period that would result in, at earliest, a March 2017 launch of the treatment. AbbVie, the maker of adalimumab (Humira), has sued Amgen for patent infringement for its 10 indications. AbbVie has asked the court to block Amgen’s drug if and when the FDA issues an approval.2 Time will tell.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Food and Drug Administration. News release: FDA approves Amjevita, a biosimilar to Humira. 2016 Sep 24
  2. Staton T. Amgen’s Humira biosim, Amjevita, passes FDA milestone on long road to market. FiercePharma, 2016 Sep 23.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, adalimumab-atto, Biosimilars, FDA, Food and Drug Administration

You Might Also Like:
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
  • FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)